Cerapedics Announces FDA approval of an IDE supplement

IDE Supplement allows for a reduction in the total number of patients required to be enrolled in the ASPIRE IDE Study on P15-L bone graft in the lumbar spine WESTMINSTER, Colo., July 22, 2020 -- (Healthcare Sales & Marketing Network) -- Cerapedics, a p... Devices, Orthopaedic, Neurosurgery, FDA Cerapedics, Bone Graft, transforaminal, lumbar interbody fusion

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2046179

Source: HSMN NewsFeed - July 22, 2020 Category: Pharmaceuticals Source Type: news